STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for hard-to-treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, MOR00208 and lenalidomide, in 41 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination could shrink or control the cancer. Participants had either not been treated before or ha…
Matched conditions: STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New combo shows promise against tough lymphomas
Disease control CompletedThis study tested a combination of the drug lenalidomide with standard chemotherapy (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the safest dose and see how well the treatment controls the cancer. Results help guide future t…
Matched conditions: STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
Can ibrutinib wipe out leftover leukemia cells?
Disease control CompletedThis study tested the drug ibrutinib in 35 people with chronic lymphocytic leukemia (CLL) who still had small amounts of cancer after their first treatment. The goal was to see if ibrutinib could make those leftover cancer cells disappear completely. Participants took ibrutinib p…
Matched conditions: STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 08, 2026 13:03 UTC